Author:
Kim In-Cheol,Youn Jong-Chan,Jang Se Yong,Lee Sang Eun,Cho Hyun-Jai,Choi Jin-Oh,Lee Ju-Hee,Kim Kyung-Hee,Lee Sun Hwa,Kim Kye Hun,Lee Jong Min,Yoo Byung-Su,Yoo Byung-Su,Jang Se Yong,Lee Jong Min,Kim In-Cheol,Choi Jin-Oh,Cho Hyun-Jai,Lee Sang Eun,Kim Kyung-Hee,Kim Kye Hun,Lee Sun Hwa,Lee Ju-Hee,Choi Jung Hyun,Oh Jaewon,Seo Suk Min,Park Jin Joo,Kim Jeong Su,Hwang Seok-Jae,Park Jae-Hyeong,Park Sang Min,Kim Eung Ju,Youn Jong-Chan,Ihm Sang-Hyun,Ha Sang Jin,Chung Wook-Jin,Choi Seong Hoon,Kim Ji-Hyun,Kim Song-Yi,Cho Kyoung Im,Ryu Dong Ryeol,
Abstract
AbstractThis Korean nationwide, multicenter, noninterventional, prospective cohort study aimed to analyze physician adherence to guideline-recommended therapy for heart failure (HF) with reduced ejection fraction (HFrEF) and its effect on patient-reported outcomes (PROs). Patients diagnosed with or hospitalized for HFrEF within the previous year were enrolled. Treatment adherence was considered optimal when all 3 categories of guideline-recommended medications (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin inhibitors; beta-blockers; and mineralocorticoid receptor antagonists) were prescribed and suboptimal when ≤ 2 categories were prescribed. The 36-Item Short Form Survey (SF-36) scores were compared at baseline and 6 months between the 2 groups. Overall, 854 patients from 30 hospitals were included. At baseline, the optimal adherence group comprised 527 patients (61.7%), whereas during follow-up, the optimal and suboptimal adherence groups comprised 462 (54.1%) and 281 (32.9%) patients, respectively. Patients in the suboptimal adherence group were older, with a lower body mass index, and increased comorbidities, including renal dysfunction. SF-36 scores were significantly higher in the optimal adherence group for most domains (P < 0.05). This study showed satisfactory physician adherence to contemporary treatment for HFrEF. Optimal adherence to HF medication significantly correlated with better PROs.
Publisher
Springer Science and Business Media LLC